Cancer vaccines have been a promise of oncology for more than three decades, with mixed and often disappointing results in the clinic. That history is part of why the announcement on August 19, 2026, from Merck (known as MSD outside the United States and Canada) and Moderna carries weight. Their experimental therapy, intismeran autogene — also known by its earlier development codes, V940 and mRNA-4157 — has become the first individualized neoantigen therapy, and the first mRNA-based cancer therapy of any kind, to meet its primary endpoint in a Phase 3 trial [1]. Given together with the anti-PD-1 immunotherapy pembrolizumab (Keytruda®; Merck & Co/MSD), the combination reduced the risk of melanoma recurrence and distant spread in patients whose tumors had already been surgically removed [1].
The result matters not because it is dramatic in isolation — the companies have not yet released the actual magnitude of benefit, holding those numbers for a forthcoming medical meeting — but because of what it represents structurally. This is a cancer treatment manufactured individually, from a single patient’s own tumor tissue, and it has now cleared the largest and most rigorous bar in clinical research: a randomized, controlled, late-stage trial. For a field that has watched personalized cancer vaccines fail to reach this point for a generation, that alone is a milestone worth explaining carefully.
Therapeutic, Not Preventive: A Different Kind of Vaccine
The word “vaccine” invites a natural assumption — that this is a shot given to healthy people to prevent melanoma from occurring in the first place, the way an HPV vaccine helps prevent cervical cancer caused by the virus. That is not what intismeran autogene does.
This is a therapeutic cancer vaccine, not a prophylactic one. It is given after a diagnosis has already been made and after the tumor has already been surgically removed, with the specific goal of preventing that particular cancer from coming back. The distinction is fundamental. A prophylactic vaccine trains the immune system in advance against a threat the body has not yet encountered, usually a virus or a well-defined, shared molecular target present in essentially everyone who receives the shot. A therapeutic cancer vaccine like this one is reactive and individualized: it is designed after the disease is already present, built from the genetic mutations found in that specific patient’s own tumor, and aimed at mopping up microscopic disease that imaging cannot detect, before it has the chance to regrow.
This is also why intismeran autogene is not interchangeable with other mRNA products people may be more familiar with. The mRNA-based Covid-19 vaccines instruct cells to produce a viral protein — the SARS-CoV-2 spike protein — that is essentially identical in every recipient, so a single formulation can be manufactured at scale and given to millions of people. Intismeran autogene instructs cells to produce protein fragments unique to one patient’s cancer. No two doses are alike, because no two tumors carry the same combination of mutations.
How It Works: Reading a Tumor’s Mutational Fingerprint
The manufacturing process begins with tissue from the patient’s resected tumor, along with a blood sample as a normal-tissue comparator. Researchers sequence the tumor’s DNA and RNA to identify the mutations unique to that cancer. A bioinformatics algorithm then analyzes those mutations to predict which ones are most likely to be recognized by the immune system and to prompt a meaningful T-cell response, a process the developers describe as identifying the tumor’s mutational “fingerprint” [1].
From that shortlist, up to 34 selected mutations — known as neoantigens because they are new proteins not found in healthy cells — are encoded into a single strand of synthetic messenger RNA [1]. Once injected, that mRNA is taken up by the patient’s own cells, which read the genetic instructions and produce the corresponding neoantigen protein fragments. The immune system then encounters these fragments, presented on the surface of cells, and mounts a T-cell response specifically tailored to recognize and attack any remaining cancer cells that carry those same mutations, should they be present in the body. Encoding up to 34 targets in one dose is a deliberate hedge against tumor heterogeneity and immune escape: if a cancer cell manages to lose or mask one mutated protein, T-cells trained against the other targets may still find and destroy it.
In INTerpath-001, intismeran autogene was administered every three weeks for up to nine doses, alongside pembrolizumab administered every six weeks for up to nine cycles, for a total treatment period of approximately 56 weeks [1] [2]. Pembrolizumab works through an entirely different mechanism: it is an antibody that blocks the PD-1 receptor on T-cells, interrupting a signal that cancer cells often use to switch off an immune attack against them [8]. The pairing is intentional. The vaccine’s job is to train and expand an army of cancer-specific T-cells; pembrolizumab’s job is to remove the brakes those T-cells would otherwise encounter once they reach the tumor microenvironment.
What Is New: The Phase 3 INTerpath-001 Results
INTerpath-001 (ClinicalTrials.gov identifier NCT05933577) enrolled 1,137 patients with completely resected stage IIB, IIC, III, or IV cutaneous melanoma who had not previously received systemic treatment for their cancer [1] [2]. Patients were randomized two-to-one to receive either intismeran autogene combined with pembrolizumab, or pembrolizumab alone — the existing standard of care for many of these patients following surgery [1].
The trial met its primary endpoint, recurrence-free survival, with a statistically significant and clinically meaningful improvement for the combination compared with pembrolizumab alone [1]. It also met a key secondary endpoint, distant metastasis-free survival, meaning the combination reduced not just local or regional recurrence but also the spread of melanoma to distant organs [1]. A further secondary endpoint, overall survival, has not yet matured and will continue to be followed as the study proceeds [1]. The companies reported that the safety profile of the combination in this larger trial was consistent with prior studies, with no new safety signals identified [1].
What has not yet been disclosed is the actual size of the effect — the hazard ratios and confidence intervals that would let a clinician judge, in concrete terms, how much this combination outperforms pembrolizumab alone. Merck and Moderna have said that detailed data will be presented at an upcoming international medical meeting and submitted to regulators, a sequencing that is standard practice for large pharmaceutical trial readouts but does mean that, for now, the “positive result” is a company characterization of the data rather than a peer-reviewed finding the broader oncology community can independently evaluate.
The Foundation: What Phase 2 Already Showed
INTerpath-001’s design was built on an earlier, considerably smaller trial, the Phase 2b KEYNOTE-942 study (NCT03897881), which enrolled 157 patients with completely resected high-risk stage IIIB-IV cutaneous melanoma. Its results, published in The Lancet, showed that adjuvant intismeran autogene (referred to in the paper by its earlier name, mRNA-4157/V940) plus pembrolizumab prolonged recurrence-free survival compared with pembrolizumab alone, with a manageable safety profile [3]. At three years of follow-up, presented at the American Society of Clinical Oncology (ASCO) annual meeting, the combination was associated with a 49% reduction in the risk of recurrence or death and a 62% reduction in the risk of distant metastasis or death compared with pembrolizumab alone [4]. A five-year update, also published in ASCO’s Journal of Clinical Oncology, showed that the recurrence-free survival benefit persisted at a similar magnitude, with longer-term distant metastasis data to be presented at a future meeting [5]. Commentary accompanying the original Lancet publication in Nature Reviews Clinical Oncology described the findings as evidence that a personalized neoantigen mRNA vaccine could measurably reduce the odds of melanoma returning after surgery [6].
It is worth being precise about scale: KEYNOTE-942 enrolled roughly one-seventh as many patients as INTerpath-001, in a somewhat narrower disease population confined to stage IIIB-IV rather than IIB-IV. Those earlier numbers illustrate the size of benefit the Phase 3 trial was designed to confirm; they are not a substitute for INTerpath-001’s own, still-unpublished effect size.
How Patients May Benefit
The intended benefit for patients is straightforward to describe, even before the full numbers are public: for people who have had a high-risk melanoma completely removed by surgery, this approach aims to lower the chance that the cancer returns, either at the original site or at a distant location in the body, beyond what pembrolizumab alone already achieves. This matters because resected high-risk melanoma still carries a substantial risk of recurrence, most often within the first two years after surgery, and the majority of recurrences are metastatic rather than confined to the original site [1]. A therapy that meaningfully extends the time patients remain cancer-free, or reduces the likelihood that melanoma spreads to distant organs, addresses one of the most consequential unmet needs in this setting.
There is also a conceptual benefit worth naming: because the vaccine is built from each patient’s own tumor rather than a single shared target, it is designed to work even when different patients’ melanomas carry entirely different mutations — a common obstacle for earlier, one-size-fits-all cancer vaccines, which struggled when tumors evaded an immune response aimed at a single shared feature.
Regulatory Status
Intismeran autogene in combination with pembrolizumab remains investigational; it is not yet approved anywhere for clinical use. Based on the Phase 2b KEYNOTE-942 data, the U.S. Food and Drug Administration granted the combination Breakthrough Therapy Designation in February 2023, specifically for the adjuvant treatment of patients with high-risk melanoma following complete resection [7]. The European Medicines Agency granted the equivalent PRIME (PRIority MEdicines) designation shortly afterward [7]. Both designations are mechanisms intended to speed up the development and regulatory review of therapies that show early promise against a serious condition; neither constitutes approval, and neither substitutes for the Phase 3 evidence that regulators will now formally review. Following the INTerpath-001 topline results, Merck and Moderna have said they plan to engage with regulatory authorities on filing submissions for the combination [1].
Which Diagnoses Are Involved
The population studied in INTerpath-001, and the one for which regulatory filings would apply if the therapy is ultimately approved, is patients with completely resected cutaneous melanoma at stage IIB, IIC, III, or IV who have not received prior systemic therapy [1]. This is an adjuvant setting: the tumor has already been removed surgically, and the treatment is given afterward to reduce the risk that the cancer returns. It is not a treatment for active, unresected, or unresectable melanoma, and it is not designed to prevent melanoma in people who have never had the disease.
Beyond melanoma, Merck and Moderna are running a broader INTerpath clinical development program, currently comprising nine Phase 2 and Phase 3 trials across additional tumor types, including non-small cell lung cancer, bladder cancer, and renal cell carcinoma, along with earlier-stage studies in pancreatic, gastric, and additional lung cancer settings [1]. None of that work changes what has been demonstrated so far; it indicates where the same individualized approach is being tested next.
Is a Companion Diagnostic Required?
Companion diagnostics (CDx) have become a central feature of precision oncology. Their purpose is to identify, in advance, which patients are most likely to benefit from a given targeted therapy, and they are now well established across many targeted drugs. The role of CDx testing is also expanding into newer treatment classes: for antibody-drug conjugates, biomarker testing can determine whether a tumor expresses the specific antigen the ADC is built to target, which in turn helps decide whether that ADC is an appropriate choice for that patient. CAR T-cell therapies rely on a related logic, since their engineered receptors are built to recognize one fixed, predetermined target antigen; assessing whether that antigen is present is central to these therapies as well, even though such assessments are not always formally classified as companion diagnostics in the regulatory sense. Across all of these examples, an important principle holds: the mere presence of a therapeutic target does not automatically make a test a companion diagnostic. That designation requires clinical evidence that the biomarker is genuinely predictive of benefit, or necessary for selecting appropriate patients, not simply that the target happens to exist.
Intismeran autogene does not fit this model, because it is not built around one fixed, shared target that a diagnostic test would need to confirm is present or absent. There is no single antigen to screen for, and so there is no biomarker-positive or biomarker-negative population to separate with a conventional CDx. Instead, every patient’s tumor is presumed to carry its own distinct set of mutations, and the sequencing step exists to characterize those mutations, not to determine eligibility for the drug in the way a CDx would. That said, tumor and normal-tissue sequencing is still an absolute requirement for every patient: it is the process by which each individual’s neoantigens are identified and the manufacturing blueprint for their personal vaccine is generated. In that sense, the sequencing and bioinformatics analysis functions as a mandatory, patient-specific prerequisite for treatment, but it plays the role of a manufacturing input rather than a companion test that sorts patients into eligible or ineligible groups ahead of a standardized drug. There is, at this stage, no separate approved companion diagnostic product associated with the combination, since the therapy itself cannot exist without individualized tumor sequencing as its first manufacturing step.
What Remains Unknown
Several things are still outstanding. The actual magnitude of the INTerpath-001 benefit — the hazard ratios, confidence intervals, and absolute differences in recurrence rates between the two study arms — has not been released and is expected at an upcoming international medical meeting, with a peer-reviewed publication to follow [1]. Overall survival data, arguably the measure of greatest interest to patients and clinicians, is still being collected [1]. And while a five-year Phase 2b follow-up offers reassurance that responses can be durable, the Phase 3 population is larger and slightly broader in stage, so its own long-term data will need to mature before those questions are fully answered for this specific trial.
How Does This Compare to CAR T-Cell Therapy?
Because both approaches are described as “personalized” and both ultimately depend on T-cells to kill cancer, intismeran autogene is sometimes mentioned alongside CAR T-cell therapy, another individualized cellular treatment already approved for certain blood cancers. The two share a starting point: each is built by analyzing an individual patient’s own tissue and designing a treatment specific to that patient, and each succeeds only if T-cells — the immune system’s primary cancer-killing cells — carry out the actual attack [9]. Beyond that, they work in fundamentally different ways. CAR T-cell therapy is a form of adoptive cell therapy: a patient’s own T-cells are physically removed from the body, genetically re-engineered in a specialized laboratory to express a chimeric antigen receptor (CAR) that recognizes a specific, predetermined marker on cancer cells, expanded to large numbers, and then infused back into the patient, typically only at accredited treatment centers equipped to manage the infusion and its potential side effects [9]. Intismeran autogene never removes or modifies any cells at all. It is a synthetic mRNA molecule given as an injection; the genetic engineering, so to speak, happens inside the patient’s own body, where the mRNA simply instructs existing cells to display neoantigen protein fragments so the immune system can learn to recognize them on its own. CAR T-cell products are also typically engineered against a single, fixed target shared across patients with a given cancer type, such as the CD19 marker common to certain B-cell leukemias and lymphomas, whereas intismeran autogene encodes up to 34 targets drawn directly from one patient’s individual tumor mutations, with a different set of targets for essentially every patient who receives it [1]. In short: both are personalized, T-cell-driven strategies, but one re-engineers cells outside the body in a laboratory, while the other reprograms the immune response from within, using a drug rather than a modified living cell.
A Cautious but Genuine Milestone
Personalized cancer vaccines have been pursued for decades, with a long track record of encouraging early data that did not hold up in larger, randomized trials. INTerpath-001 does not erase that history, and the details that would let clinicians weigh this therapy against existing options are still to come. What it does represent, based on what has been disclosed so far, is the first time an individualized neoantigen therapy — and the first time any mRNA-based cancer therapy — has met its primary endpoint in a Phase 3 trial [1]. For a therapeutic category that has spent years working to reach exactly this point, that is a genuine, if still incomplete, step forward.
Note: Intismeran autogene remains investigational and does not have an approved prescribing label.
Clinical trials
INTerpath-001 (NCT05933577): Randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 trial evaluating intismeran autogene plus pembrolizumab versus pembrolizumab alone in 1,137 patients with completely resected stage IIB-IV cutaneous melanoma. Primary endpoint: recurrence-free survival. Key secondary endpoints: distant metastasis-free survival, overall survival, safety, tolerability, and quality of life. Status: primary and key secondary endpoints met; overall survival follow-up ongoing.
KEYNOTE-942 / mRNA-4157-P201 (NCT03897881): Randomized, open-label Phase 2b trial of the same combination in 157 patients with completely resected high-risk stage IIIB-IV cutaneous melanoma. Closed to accrual; long-term follow-up (through five years) reported.
Additional INTerpath program studies are ongoing in non-small cell lung cancer, bladder cancer, renal cell carcinoma, and other tumor types, evaluating intismeran autogene in combination with pembrolizumab, other anti-cancer therapies, and as monotherapy.
Highlights of Prescribing Information
Pembrolizumab (Keytruda®; Merck & CO/MSD)[Prescribing Information] is an anti-PD-1 monoclonal antibody indicated, among other uses, for the adjuvant treatment of adult and pediatric patients (12 years and older) with Stage IIB, IIC, or III melanoma following complete resection, and for the treatment of patients with unresectable or metastatic melanoma [8]. KEYTRUDA carries a Boxed Warning-adjacent set of Warnings and Precautions for immune-mediated adverse reactions, including pneumonitis, colitis, hepatotoxicity, endocrinopathies, nephritis, and skin reactions, which can occur in any organ system and at any time during or after treatment; severe or fatal cases have been reported [8]. Other risks include infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicity. This is not a complete summary of safety information. Full Prescribing Information and Medication Guide for KEYTRUDA are available at merck.com.
Reference
[1] Merck & Co. Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma. Press release. August 19, 2026.
[2] ClinicalTrials.gov. A Study of V940 (mRNA-4157) With Pembrolizumab Versus Placebo With Pembrolizumab in Participants With High-Risk Melanoma After Complete Resection (INTerpath-001). Identifier NCT05933577.
[3] Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632-644.
[4] Khattak MA, Carlino MS, Meniawy T, et al. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. J Clin Oncol. 2024;42(suppl 17):LBA9512.
[5] Weber JS, Khattak MA, Carlino MS, et al. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. J Clin Oncol. 2026 (online ahead of print).
[6] Killock D. Personalized neoantigen mRNA vaccine mitigates melanoma recurrence. Nat Rev Clin Oncol. 2024;21:168.
[7] Moderna, Inc. and Merck & Co. Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination With KEYTRUDA® (pembrolizumab), Granted Breakthrough Therapy Designation by the U.S. FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection. Press release. February 2023.
[8] Merck & Co. KEYTRUDA® (pembrolizumab) Injection, for Intravenous Use: Highlights of Prescribing Information. Available at: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
[9] National Cancer Institute. NCI Dictionary of Cancer Terms: chimeric antigen receptor T-cell therapy (CAR T-cell therapy). Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/chimeric-antigen-receptor-t-cell-therapy
Featured image © 2013 – 2026 Fotolia/Adobe. Used with permission.
DOI
